UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS.
“After the Ecstasy, the Laundry” – Shayla Love’s take on psychedelics in 2022 – Psychedelic Alpha
Themes that shaped the psychedelics space in 2022, plus her hopes and predictions for the coming year.
Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients
Findings suggest that psilocybin-assisted therapy facilitates psycho-social-spiritual growth as measured by the NIH-HEALS and its three factors.
Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals
We here show that lasting changes in trait mindfulness following psilocybin administration are positively associated with intensity of the mystical-type experience.
Small Pharma reports positive top-line results from phase IIa trial of SPL026 in major depressive disorder
intravenous N,N-Dimethyltryptamine (“DMT”), with supportive therapy for the treatment of MDD met the primary endpoint in its Phase IIa clinical trial.
Psychedelic integration challenges: Participant experiences after a psilocybin truffle retreat in the Netherlands
We discuss the implications for psychedelic integration and harm reduction practices and for future psychedelic research.
Psychedelics for patients with cancer: A comprehensive literature review
Psychedelics have a unique mechanism of action that might be well suited for treating anxiety and depression associated with cancer.
Is the high cost of psychedelic therapy worth it?
In this column I will examine the costs and benefits of psychedelic-assisted therapy,
Could ketamine-assisted therapy help treat alcohol disorder?
A new £2.4 million phase III trial delivered through seven NHS sites across the UK will investigate whether ketamine-assisted therapy could help treat alcohol disorder.
Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness
Results suggest that experience with psilocybin is the only reliable (and strongest) predictor of Nature Relatedness.
The bright side of psychedelics: Latest advances and challenges in neuropharmacology
The most recent clinical studies evaluating the efficacy of psychedelic molecules in some psychiatric disorders are discussed and compared with drugs already used in therapy.
“A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use
Our findings demonstrate both benefits and risks of psilocybin use in this population. Carefully designed clinical trials focused on safety and preliminary efficacy are warranted.
Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption
The subjective benefits of psilocybin use for mental health symptoms reported by survey participants encourage further investigation of psilocybin-based treatments for BD.
Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial
These results suggest that a single, moderate dose of psilocybin significantly reduces depressive symptoms compared to a placebo condition for at least two weeks.
Psychedelics and mortality: A conversation with Roland Griffiths
Sam Harris speaks with Roland Griffiths about psychedelics and mortality.
Psychedelic science of spirituality and religion: An attachment-Informed agenda proposal
we discuss the role of religion and spirituality in psychedelic experiences from an attachment perspective.
Entheogenic spirituality: Characteristics of spiritually motivated psychedelics use
The study affirms the existence of a movement of spiritually motivated entheogen users that requires further investigation.